Lynparza breast cancer Clinical Experience Investigation

Trial Identifier: D0819C00005
Sponsor: AstraZeneca
NCTID:: NCT03590938
Start Date: August 2018
Primary Completion Date: March 2022
Study Completion Date: March 2022
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Aichi, Japan, D0819C00005
Japan Aomori, Japan, D0819C00005
Japan Chiba, Japan, D0819C00005
Japan Ehime, Japan, D0819C00005
Japan Fukui, Japan, D0819C00005
Japan Fukuoka, Japan, D0819C00005
Japan Gunma, Japan, D0819C00005
Japan Hiroshima, Japan, D0819C00005
Japan Hokkaido, Japan, D0819C00005
Japan Hyogo, Japan, D0819C00005
Japan Ibaraki, Japan, D0819C00005
Japan Ishikawa, Japan, D0819C00005
Japan Iwate, Japan, D0819C00005
Japan Kagawa, Japan, D0819C00005
Japan Kagoshima, Japan, D0819C00005
Japan Kanagawa, Japan, D0819C00005
Japan Kochi, Japan, D0819C00005
Japan Kumamoto, Japan, D0819C00005
Japan Kyoto, Japan, D0819C00005
Japan Miyagi, Japan, D0819C00005
Japan Nagano, Japan, D0819C00005
Japan Nara, Japan, D0819C00005
Japan Okayama, Japan, D0819C00005
Japan Okinawa, Japan, D0819C00005
Japan Osaka, Japan, D0819C00005
Japan Saitama, Japan, D0819C00005
Japan Shiga, Japan, D0819C00005
Japan Shimane, Japan, D0819C00005
Japan Shizuoka, Japan, D0819C00005
Japan Tokyo, Japan, D0819C00005
Japan Toyama, Japan, D0819C00005
Japan Yamagata, Japan, D0819C00005
Japan Yamaguchi, Japan, D0819C00005
Japan Yamanashi, Japan, D0819C00005